within Pharmacolibrary.Drugs.ATC.G;

model G04BD14
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.45,
    Cl             = 0.00047,
    adminDuration  = 600,
    adminMass      = 0.2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0125,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.025833333333333333,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.0312,
    k12             = 21.8,
    k21             = 21.8
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G04BD14</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Imidafenacin is a muscarinic receptor antagonist used primarily for the treatment of overactive bladder and urinary incontinence. It is approved and marketed in Japan and some other Asian countries, but not in the United States or Europe.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were reported in healthy adult male volunteers after single oral dosing.</p><h4>References</h4><ol><li><p>Ohno, T, et al., &amp; Miyata, Y (2008). Absolute bioavailability of imidafenacin after oral administration to healthy subjects. <i>British journal of clinical pharmacology</i> 65(2) 197–202. DOI:<a href=\"https://doi.org/10.1111/j.1365-2125.2007.02999.x\">10.1111/j.1365-2125.2007.02999.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18251758/\">https://pubmed.ncbi.nlm.nih.gov/18251758</a></p></li><li><p>Inoue, K, et al., &amp; Kamoto, T (2011). [Investigation of pharmacokinetics of crushed imidafenacin 0.1-mg tablet after single oral administration in healthy men]. <i>Hinyokika kiyo. Acta urologica Japonica</i> 57(12) 677–681. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22240300/\">https://pubmed.ncbi.nlm.nih.gov/22240300</a></p></li><li><p>Ohno, T, et al., &amp; Ohnishi, A (2008). Effect of itraconazole on the pharmacokinetics of imidafenacin in healthy subjects. <i>Journal of clinical pharmacology</i> 48(3) 330–334. DOI:<a href=\"https://doi.org/10.1177/0091270007310386\">10.1177/0091270007310386</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18218784/\">https://pubmed.ncbi.nlm.nih.gov/18218784</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G04BD14;
